X Bioscience PCL (BKK:XBIO)

X Bioscience PCL Statistics

Total Valuation

BKK:XBIO has a market cap or net worth of THB 850.56 million. The enterprise value is 1.09 billion.

Market Cap	850.56M
Enterprise Value	1.09B

Important Dates

The last earnings date was Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

BKK:XBIO has 12.15 billion shares outstanding. The number of shares has increased by 118.21% in one year.

Current Share Class	12.15B
Shares Outstanding	12.15B
Shares Change (YoY)	+118.21%
Shares Change (QoQ)	+156.98%
Owned by Insiders (%)	66.18%
Owned by Institutions (%)	n/a
Float	4.10B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.56
PB Ratio	3.81
P/TBV Ratio	38.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.33
EV / Sales	8.43
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.85

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 1.08.

Current Ratio	0.93
Quick Ratio	0.05
Debt / Equity	1.08
Debt / EBITDA	n/a
Debt / FCF	-3.05
Interest Coverage	-17.33

Financial Efficiency

Return on equity (ROE) is -86.14% and return on invested capital (ROIC) is -82.74%.

Return on Equity (ROE)	-86.14%
Return on Assets (ROA)	-28.06%
Return on Invested Capital (ROIC)	-82.74%
Return on Capital Employed (ROCE)	-160.25%
Weighted Average Cost of Capital (WACC)	4.34%
Revenue Per Employee	324,948
Profits Per Employee	-1.18M
Employee Count	399
Asset Turnover	0.13
Inventory Turnover	10.88

Taxes

Income Tax	-3.25M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -93.33% in the last 52 weeks. The beta is -0.20, so BKK:XBIO's price volatility has been lower than the market average.

Beta (5Y)	-0.20
52-Week Price Change	-93.33%
50-Day Moving Average	0.07
200-Day Moving Average	0.77
Relative Strength Index (RSI)	52.86
Average Volume (20 Days)	26,969,550

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BKK:XBIO had revenue of THB 129.65 million and -468.87 million in losses. Loss per share was -1.17.

Revenue	129.65M
Gross Profit	53.04M
Operating Income	-454.31M
Pretax Income	-455.74M
Net Income	-468.87M
EBITDA	-436.40M
EBIT	-454.31M
Loss Per Share	-1.17

Balance Sheet

The company has 4.66 million in cash and 240.36 million in debt, with a net cash position of -235.69 million or -0.02 per share.

Cash & Cash Equivalents	4.66M
Total Debt	240.36M
Net Cash	-235.69M
Net Cash Per Share	-0.02
Equity (Book Value)	223.20M
Book Value Per Share	0.21
Working Capital	-24.09M

Cash Flow

In the last 12 months, operating cash flow was -75.29 million and capital expenditures -3.59 million, giving a free cash flow of -78.88 million.

Operating Cash Flow	-75.29M
Capital Expenditures	-3.59M
Depreciation & Amortization	17.90M
Net Borrowing	-100.62M
Free Cash Flow	-78.88M
FCF Per Share	-0.01

Margins

Gross Margin	40.91%
Operating Margin	-350.40%
Pretax Margin	-351.50%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

BKK:XBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-118.21%
Shareholder Yield	-118.21%
Earnings Yield	-55.12%
FCF Yield	-9.27%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on October 3, 2025. It was a reverse split with a ratio of 0.1428571429.

Last Split Date	Oct 3, 2025
Split Type	Reverse
Split Ratio	0.1428571429

Scores

BKK:XBIO has an Altman Z-Score of -5.94 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.94
Piotroski F-Score	3